胎儿LAK细胞治疗中晚期肝癌的疗效观察

The Effect of Fetal LAK Cells in the Treatment of Advanced Liver Cancer

自１９８９年１月至１９９１年１０月，我们应用６－７个月龄的胎儿脾脏细胞和白细胞介素－２共培养３天后制备成胎儿ＬＡＫ细胞，静脉输注或肝动脉插管灌注治疗中晚期肝癌１８例。结果疼痛减轻１６例，占８８．９％；食欲增加１４例，占７７％；临床完全缓解２例，占１１％；部分缓解１４例，占７７％；总有效率占８８．９％（１６／１８）。而且ＬＡＫ细胞治疗后患者周围血ＬＫＴ４比率升高，ＯＬＴ８比率下降。

From January 1989 to October 1991,18 patients with advanced liver cancer were treated with LAK cells from 6-7 months old fetus spleen cells cultured with IL-2 for 3 days. The LAK cells were given intravenously or via hepatic arterial infusion. Pain relief was seen in 16 cases(88. 9%) .appetite bettered off in 14 cases(77%);CR of tumor was seen in 2 cases(11%)(PR in 14 cases(77%). An overall response rate of 88. 9% (16/18)was achieved. The fact that the ratio of OKT4 in peripheral blood of patient treated with LAK cells increased and the ratio of OKT8 declined,demonstrated enhancement of immunity after treatment. It is concluded that(1)There are abundant pre-LAK cells in fetal spleem(2)Fetal LAK cells has significant therapeutic effect in advanced liver cancer.